Numerous Case Reports of Occlusive Retinal Vasculitis and Vision Loss in Patients Following Beovu Injections (Posted by Tom Lamb at DrugInjuryWatch.com) As early as May 2020 it was suggested by the authors of an Editorial piece published online by the American Journal of Ophthalmology that the use of Beovu injections should be suspended until the underlying cause of Beovu-associated inflammation i

Recent Bevou Label Change in Europe Adds Information About Retinal Vasculitis and Retinal Vascular Occlusion (Posted by Tom Lamb at DrugInjuryWatch.com) In mid-September 2020 Novartis announced the results of a Phase 3 head-to-head study comparing its relatively new eye medicine Beovu to Eylea, a more well-established competing eye drug product from Regeneron. According to Novartis, this study sho

Belviq Safety Data Review Found Higher Rates of Colorectal Cancer, Pancreatic Cancer, and Lung Cancer (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA's decision to request that the pharmaceutical company Eisai recall its oral weight-loss drugs Belviq and Belviq XR (lorcaserin) earlier this year has been more fully explained in a new medical journal article written by FDA staff. This FDA Belviq